Discontinuing disease-modifying multiple sclerosis therapies

Affiliations

¹ Division of Neurology, Department of Medicine, University of Toronto, Toronto, ON, Canada; Li Ka Shing Knowledge Institute, St. Michael's Hospital, Toronto, ON M5B 1W8, Canada; BARLO MS Centre, St. Michael's Hospital, Toronto, ON M5B 1W8, Canada. Electronic address: kristen.krysko@mail.utoronto.ca.

Comment

Kristen M Krysko. Lancet Neurol. 2023 Jul.

. 2023 Jul;22(7):543-545.

doi: 10.1016/S1474-4422(23)00200-4.

¹ Division of Neurology, Department of Medicine, University of Toronto, Toronto, ON, Canada; Li Ka Shing Knowledge Institute, St. Michael's Hospital, Toronto, ON M5B 1W8, Canada; BARLO MS Centre, St. Michael's Hospital, Toronto, ON M5B 1W8, Canada. Electronic address: kristen.krysko@mail.utoronto.ca.

No abstract available

Comment on

Risk of new disease activity in patients with multiple sclerosis who continue or discontinue disease-modifying therapies (DISCOMS): a multicentre, randomised, single-blind, phase 4, non-inferiority trial.
Corboy JR, Fox RJ, Kister I, Cutter GR, Morgan CJ, Seale R, Engebretson E, Gustafson T, Miller AE; DISCOMS investigators. Corboy JR, et al. Lancet Neurol. 2023 Jul;22(7):568-577. doi: 10.1016/S1474-4422(23)00154-0. Lancet Neurol. 2023. PMID: 37353277 Clinical Trial.